and protected rat gastric mucosa from ulceration in indomethacin and orthophen ulcer models at
a dose of 50 mg
Dobrodeeva, V.S.,
Shnayder, N.A.,
Novitsky, M.A.,
Asadullin, A.R.,
Vaiman, E.E.,
Petrova, M.M.,
Limankin, O.V.,
Neznanov, N.G.,
Garganeeva, N.P.,
Nasyrova, R.F. (2022) in the treatment of schizophrenia spectrum disorders (SSDs). The efficiency of APs is based on
a range of target
Khazhiev, S.Y.,
Khusainov, M.A.,
Khalikov, R.A.,
Kataev, V.A.,
Tyumkina, T.V.,
Mescheryakova, E.S.,
Khalilov, L.M.,
Kuznetsov, V.V. (2022) -trichloromethyl-1,3-dioxane in the crystalline phase and in solution have
a chair conformation with an equatorial
Vaiman, E.E.,
Shnayder, N.A.,
Zhuravlev, N.M.,
Petrova, M.M.,
Asadullin, A.R.,
Al-Zamil, M.,
Garganeeva, N.R.,
Shipulin, G.A.,
Cumming, G.,
Nasyrova, R.F. (2022) (LQTS) as
a cardiac adverse drug reaction is
a multifactorial symptomatic disorder,
the development
Gilyazova, I.R.,
Ivanova, E.A.,
Bermisheva, M.A.,
Loginova, M.V.,
Asadullina, D.D.,
Ishemgulov, R.R.,
Mustafin, A.T.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2022) of PTEN, rs17878362 of TP53, and rs2699887 of PIK3CA with the risk of prostate cancer development. As
a